Details for Patent: 9,675,704
✉ Email this page to a colleague
Which drugs does patent 9,675,704 protect, and when does it expire?
Patent 9,675,704 protects DYANAVEL XR 10, DYANAVEL XR 15, DYANAVEL XR 20, and DYANAVEL XR 5, and is included in one NDA.
This patent has twenty-one patent family members in fourteen countries.
Summary for Patent: 9,675,704
| Title: | Modified release formulations containing drug-ion exchange resin complexes |
| Abstract: | A particulate, pH-independent, modified release barrier coated drug-cation exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. Methods of making and products containing this coated complex are described. |
| Inventor(s): | Ketan Mehta, Yu-Hsing Tu |
| Assignee: | Tris Pharma Inc |
| Application Number: | US15/200,786 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,675,704 |
|
Patent Claim Types: see list of patent claims | Composition; Dosage form; |
Drugs Protected by US Patent 9,675,704
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | DYANAVEL XR 10 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-002 | Nov 4, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Tris Pharma Inc | DYANAVEL XR 15 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-003 | Nov 4, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Tris Pharma Inc | DYANAVEL XR 20 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-004 | Nov 4, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Tris Pharma Inc | DYANAVEL XR 5 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-001 | Nov 4, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,675,704
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E536867 | ⤷ Start Trial | |||
| Australia | 2007227569 | ⤷ Start Trial | |||
| Brazil | PI0709606 | ⤷ Start Trial | |||
| Canada | 2645855 | ⤷ Start Trial | |||
| China | 101400343 | ⤷ Start Trial | |||
| China | 102488652 | ⤷ Start Trial | |||
| Denmark | 2018160 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
